比较有晶状体眼与人工晶状体眼在接受地塞米松植入物治疗糖尿病性黄斑水肿中的真实世界研究:PHAKIDEX研究
这项在法国开展的多中心回顾性研究纳入328只接受地塞米松植入物(DEX-implant)治疗糖尿病性黄斑水肿的眼,比较有晶状体眼与人工晶状体眼的功能结局与安全性;多变量分析显示两组最佳矫正视力变化(似然比检验 P=0.09)与中心黄斑厚度变化(P=0.79)均无显著差异,有晶状体眼白内障手术率为39.9%,两组高眼压风险无统计学差异(P=0.9)。
要点
- 有晶状体眼与人工晶状体眼接受DEX-implant治疗后最佳矫正视力变化无显著差异(似然比检验 P=0.09)。
- 两组中心黄斑厚度变化无显著差异(似然比检验 P=0.79)。
- 有晶状体眼白内障手术率39.9%,平均延迟8.1个月(95%CI 6.59-9.69)。
核心结论
- 有晶状体眼接受DEX-implant治疗糖尿病性黄斑水肿与人工晶状体眼相比,视力增益无显著差异,安全性特征相当。
研究设计与样本
- 法国多中心回顾性研究,纳入连续接受DEX-implant治疗糖尿病性黄斑水肿的患眼,共328只眼:有晶状体眼158只(48.2%),人工晶状体眼167只(50.9%),3只眼状态未知。
主要发现
- 多变量分析中,有晶状体眼与人工晶状体眼的最佳矫正视力较基线平均变化无显著差异(似然比检验 P=0.09)。
- 多变量分析中,有晶状体眼与人工晶状体眼的中心黄斑厚度变化无显著差异(似然比检验 P=0.79)。
- 研究期间有晶状体眼行白内障手术者63只眼(39.9%),平均延迟8.1个月(95%CI 6.59-9.69)。
- 有晶状体眼中行与未行白内障手术者相比,随访各次访视的最佳矫正视力平均变化均无显著差异。
- 有晶状体眼与人工晶状体眼的高眼压风险无统计学差异(P=0.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dexamethasone implant (DEX-implant) is one treatment choice in diabetic macular edema. However, steroid-induced cataract is a common complication when treating a chronic disease and could lead to vision loss. Because of the lack of studies specifically focused on the functional outcomes according to the lens status, the authors therefore aim to analyze the effectiveness and safety of DEX-implant treatment for diabetic macular edema in phakic versus pseudophakic eyes. METHODS: This multicenter, retrospective study conducted in France included eyes of consecutive patients who had received a DEX-implant for diabetic macular edema. RESULTS: A total of 328 eyes were included: 158 eyes (48.2%) were phakic, 167 eyes (50.9%) were pseudophakic and three were unknown. According to the lens status, mean change in best-corrected visual acuity from baseline was never significantly different between phakic and pseudophakic eyes (likelihood ratio test, P = 0.09) nor in the change in central macular thickness (likelihood ratio test, P = 0.79) in multivariate analysis. Cataract surgery was performed in 63 phakic eyes (39.9%) during the study period with a mean delay of 8.1 months (CI95% [6.59-9.69]). The mean change in best-corrected visual acuity between phakic eyes who underwent cataract surgery and those who did not, was not significantly different during the follow-up at each visit. The risk of ocular hypertension was not statistically different between phakic and pseudophakic subsets ( P = 0.9). CONCLUSION: The authors showed here that phakic eyes treated with DEX-implant for diabetic macular edema did not have a significant difference in visual gain in comparison to pseudophakic eyes, with a comparable safety profile.
引用
- Mathis T, Rezkallah A, Ricard C, et al. REAL WORLD STUDY COMPARING PHAKIC VERSUS PSEUDOPHAKIC EYES IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT: The PHAKIDEX Study. Retina. 2023. PMID: 36977332. doi:10.1097/IAE.0000000000003787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。